Maze Therapeutics (NASDAQ:MAZE) Issues Earnings Results

Maze Therapeutics (NASDAQ:MAZE) released its quarterly earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76), Zacks reports.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock traded up $0.03 during trading on Tuesday, reaching $27.31. 379,878 shares of the stock traded hands, compared to its average volume of 669,188. Maze Therapeutics has a 52-week low of $12.81 and a 52-week high of $53.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The business has a fifty day simple moving average of $27.57 and a two-hundred day simple moving average of $33.44. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.22.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of analyst reports. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider owned 26,250 shares of the company’s stock, valued at $717,675. The trade was a 22.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares in the company, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 141,470 shares of company stock worth $3,902,714. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics in the 4th quarter valued at about $43,000. Russell Investments Group Ltd. lifted its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.